Department of Surgery, University of Pennsylvania Health System Which Operation is Best for Severe Ischemic MR: Repair or Replace? Michael Acker William.

Slides:



Advertisements
Similar presentations
Percutaneous Therapy of Pulmonic and Mitral Valve Disease Atman P. Shah MD FACC FSCAI Director, Coronary Care Unit Assistant Professor of Medicine The.
Advertisements

AVR: Choice of Prosthesis Tirone E. David University of Toronto.
Mitral valve. Repair vs. Replacement >%80 of MR are repairable Produces more physiological flow states It better preserves LV function Less thrombolic.
Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy.
Percutaneous mitral valve repair using the MitraClip® device (e-valve)
SURGICAL ABLATION OF ATRIAL FIBRILLATION DURING MITRAL VALVE SURGERY THE CARDIOTHORACIC SURGICAL TRIALS NETWORK Marc Gillinov, M.D. For the CTSN Investigators.
SURGICAL TREATMENT OF MODERATE ISCHEMIC MITRAL REGURGITATION: THE CARDIOTHORACIC SURGICAL TRIALS NETWORK Robert E. Michler, M.D. For the CTSN Investigators.
SURGICAL ABLATION OF ATRIAL FIBRILLATION DURING MITRAL VALVE SURGERY THE CARDIOTHORACIC SURGICAL TRIALS NETWORK Marc Gillinov, M.D. For the CTSN Investigators.
Ischemic MR Guidelines
Ventricular Diastolic Filling and Function
STICH Mitral Regurgitation Subanalysis Objective Examine the relationship of mitral regurgitation (MR) severity and survival and compare outcomes in patients.
How to Avoid Prosthesis-Patient Mismatch
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
Impact of Concomitant Tricuspid Annuloplasty on Tricuspid Regurgitation Right Ventricular Function and Pulmonary Artery Hypertension After Degenerative.
The Relationship Between Renal Function and Cardiac Structure, Function, and Prognosis Following Myocardial Infarction: The VALIANT Echo Study Anil Verma,
Congenital Mitral Valve Disease
AATS Grant Writing Workshop Developing a Clinical Research Program, Trial Design, Patient Enrollment Timothy J. Gardner MD Christiana Care Health System.
©2015 MFMER | Robotic Repair of Simple vs. Complex Degenerative Mitral Valve Disease Clinical and Echocardiographic Outcomes During Mid-Term.
Mitral Valve Surgery: Lessons from New York State Joanna Chikwe, MD Professor of Cardiovascular Surgery Icahn School of Medicine at Mount Sinai Chairman.
Echocardiographic predictors of perioperative atrial fibrillation EUROECHO 2010, Copenhagen, Denmark Katova T, Simova I, Nesheva A, Hristova K, Kostova.
Restrictive Physiology is a Major Predictor of Poor Outcomes in Children with Hypertrophic Cardiomyopathy Shiraz A Maskatia MD, Jamie A Decker MD, Joseph.
Impact of early surgery vs conventional treatment for infective endocarditis on mortality and embolic events: data from EASE trial Prospective RCT ( );
A Contemporary Analysis of Pulmonary Hypertension in Patients Undergoing Mitral Valve Surgery: Is this a Risk Factor? Thank you to the society and panel.
Ryan Hampton OMS IV January  Considerations Is MR severe? Is patient symptomatic? Is patient a good candidate? What is Left Ventricular function?
Intra-ventricular Papillary Muscle Head Approximation is Effective in Treating Ischemic MR in Dilated Ventricles - Comparison with Ring annuloplasty Muralidhar.
EVEREST II Study Design Multicenter Randomized in a 2:1 ratio to either percutaneous or conventional surgery for the repair or replacement of the mitral.
+ Mitral Valve Prolapse A Surgeon’s Perspective Charles Anderson, M.D. Saint Joseph’s Hospital of Atlanta.
UNIVERSITA' CAMPUS BIO-MEDICO DI ROMA Via Álvaro del Portillo, Roma - Italia Antonio Nenna, MD Department of Cardiovascular.
2-Year Outcomes following Surgical Treatment of Moderate Ischemic Mitral Regurgitation: The Cardiothoracic Surgical Trials Network Robert E. Michler,
Asymptomatic mitral regurgitation When should you operate? Ben Bridgewater Cardiac surgeon and lead clinician, UHSM, Manchester Honorary Reader, Manchester.
MITRAL RECONSTRUCTIVE SURGERY DEPARTMENT OF CARDIOTHORACIC SURGERY HOSPITAL DE SANTA MARIA LISBOA PORTUGAL.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Objective Bleeding events are grave and sometimes life threatening complications after prosthetic valve replacement, especially in hemodialysis patients.
Primary Mitral Regurgitation Degenerative Mitral Valve Disease
© free-ppt-templates.com 2017 AHA/ACC Focused Update of Valvular Heart Disease Guideline of 2014 DR. OMAR SHAHID TR CARDIOLOGY SZH.
Total Occlusion Study of Canada (TOSCA-2) Trial
Role of Device Therapy in FMR: Challenges and Opportunities
李孟霖, 蔡函衿, 陳瑞雄, 侯紹敏 國泰綜合醫院 心臟血管外科
Jeff Macemon MBChB, PDMSM Advanced Trainee, CTS
Terminology Functional MR Ischemic MR Associated MR Organic MR
CTSN Trials of Mitral Valve Repair and Replacement
3D Echo and Secondary MR Also referred to as Functional, Ischemic, Carpentier Type IIIb Dr. Bollen Dr. Shernan.
Management of mitral regurgitation. See legend for Fig
Mitral Regurgitation: Epidemiology, Pathophysiology and When to Repair
University of Pennsylvania Philadelphia
Functional MR: When to Intervene
Mitral Valve Surgery For Heart Failure
Nishith Patel Waikato Cardiothoracic Unit Journal Club
Revascularization in Patients With Left Ventricular Dysfunction:
Structural and Functional Mitral Regurgitation:
How I treat Functional Mitral Regurgitation: The Surgeon’s perspective
Early Recovery of Left Ventricular Systolic Function After CoreValve Transcatheter Aortic Valve Replacement Harold L. Dauerman, MD; Michael J. Reardon,
Dr M B Connellan Stellenbosch University
UNCERTAINTY OF RISK: THE CASE OF THE TRICUSPID DEVICES
James Hermiller, MD, FACC, FSCAI St Vincent Hospital, Indianapolis, IN
S.G. Worthley, MB, BS, PhD., S. Redwood, MD, PhD.,
Fig. 3 Summary estimates of the relative risks for the different surgical techniques for late mortality. Comparing the two main techniques, EVR showed.
Predicting recurrent mitral regurgitation after mitral valve repair for severe ischemic mitral regurgitation  Irving L. Kron, MD, Judy Hung, MD, Jessica.
Cardiovacular Research Technologies
Nishith Patel Waikato Cardiothoracic Unit
2015 The American Association for Thoracic Surgery Consensus Guidelines: Ischemic mitral valve regurgitation  Irving L. Kron, MD, Michael A. Acker, MD,
Ischemic Mitral Regurgitation
Samir R. Kapadia, MD On behalf of The PARTNER Trial Investigators
2-Year Outcomes following Surgical Treatment of Moderate Ischemic Mitral Regurgitation: The Cardiothoracic Surgical Trials Network Robert E. Michler,
Repair Techniques for Ischemic Mitral Regurgitation
Functional mitral stenosis after surgical annuloplasty for ischemic mitral regurgitation: Importance of subvalvular tethering in the mechanism and dynamic.
Michael A. Borger, MD, PhD, Patricia M
Questions and answers about the STICH trial: A different perspective
Baseline left ventricular function and surgical annular stiffening to predict outcome and reverse left ventricular remodeling after undersized annuloplasty.
Mitral valve repair in heart failure: Five-year follow-up from the mitral valve replacement stratum of the Acorn randomized trial  Michael A. Acker, MD,
Presentation transcript:

Department of Surgery, University of Pennsylvania Health System Which Operation is Best for Severe Ischemic MR: Repair or Replace? Michael Acker William Measey Professor of Surgery Chief of Division of Cardiovascular Surgery Director of Heart and Vascular Center University of Pennsylvania Health System

AHA/ACC and ESC Guidelines No conclusive evidence for superiority of repair or replacement Class I Level C evidence for IMR patients undergoing CAB w/ EF > 30% Class IIa Level C evidence for IMR patients undergoing CAB w/ EF < 30% Class IIb Level C evidence for IMR patients not undergoing CAB Class IIb Level C evidence for severe secondary MR

Treatment Choice is Controversial Lower periop morbidity and mortality with repair – Vasileva et al, Eur J Cardiothoracic Surg 2011;39: Better long-term correction with replacement – Di Salvo et al, J Am Coll Cardiol. 2010; 55: – Grossi et al, J Thorac Cardiovasc Surg 2001;122: – Gillinov et al, J Thorac Cardiovasc Surg 2001;122: Based on retrospective observational studies Need randomized evidence

4 Functional MR secondary to dilated cardiomyopathy: Bolling Hypothesis: “an annular solution for a ventricular problem”-- such that reconstruction of the MV annulus’ geometric abnormality by an undersized ring restores valvular competency, alleviates the excessive ventricular workload, improves ventricular geometry and improves ventricular function.

Department of Surgery, University of Pennsylvania Health System Mitral Annuloplasty Rings Reduce posterior annular circumference Push posterior leaflet forward for better coaptation ie decrease septal lateral dimension

Department of Surgery, University of Pennsylvania Health System MV Repair Techniques for Functional MR (Ischemic or Non-ischemic) Undersized Annuloplasty Ring- standard of care; most common of repair techniques ?Techniques to specifically address leaflet tethering— Promising but not fully tested: cutting secondary chords papillary muscle relocation

Department of Surgery, University of Pennsylvania Health System Downsized, rigid rings showed positive results at 4-year follow-up Methods: 85 consecutive patients with previous infarction, LV dysfunction (EF 30%) and severe MR underwent CABG and restrictive mitral annuloplasty with stringent downsizing (2 rigid complete ring sizes). Pre-op Pre-op 4 years p-value NYHA class < LVEDD (mm) < LVESD (mm) < LA dimension (mm) 4542<0.01 MR grade < LVEDD = left ventricle end-diastole dimension; LVESD = left ventricle end- systolic dimension; LA = left atrium Bax et al. Restrictive annuloplasty and coronary revascularization in IMR results in reverse left ventricular remodeling. Circ 110:II 103-II Braun et al: Preoperative left ventricular dimensions predict reverse remodeling following restrictive mitral annuloplasty in IMR. Eur J CT Surg 27(5): % mortality No recurrence of > 2 MR at 18 mo No reverse remodeling seen with LVEDD>65mm Cannot Discount effect of Revascularization On Hybernating Myocardium leading to Reverse Remodeling

Tethering Mechanism for recurrent MR after repair

Severe IMR Randomized Comparison of MV Repair vs Replacement Moderate/severe MR by TTE assessment in surviving pts at 30 days, 6, 12 and 24 months

Severe IMR Randomized Comparison of MV Repair vs Replacement Cumulative incidence of MR recurrence and/or death over 2 years (n=116)

11 Preservation of entire MV apparatus has been demonstrated to preserve ventricular geometry, decrease wall stress, improve systolic and diastolic function Must maintain chordal, annular and subvalvular continuity Is the Best Repair a Replacement? Comparisons of results to Era where subchordal apparatus was excised not valid

(Enriquez-Sarano et al. Circulation 2003;108: ) MV Repair vs Replacement MayMay Mayo Clinic: ICM -- no difference in survival between replacement and repair

13 Mitral valve repair or replacement for ischemic mitral regurgitation? The Italian Study on the Treatment of Ischemic Mitral Regurgitation (ISTIMIR) Lorusso R et al. J Thorac Cardiovasc Surg 2013; 145: Propensity matched

14 Mitral valve repair or replacement for ischemic mitral regurgitation? The Italian Study on the Treatment of Ischemic Mitral Regurgitation (ISTIMIR) Lorusso R et al. J Thorac Cardiovasc Surg 2013; 145:129-39

Primary Endpoint Degree of left ventricular reverse remodeling −Assessed by left ventricular end systolic volume index (LVESVI) using TTE at 12 months −Group difference based on Wilcoxon Rank-Sum test with deaths categorized as lowest LVESVI rank Powered (90%) to detect an improvement of 15mL/m 2 from repair to replacement in LVESVI at 12 months

Median change in LVESVI Change in LVESVI (mm/m 2 ) Repair Replacement Repair Replacement (All pts) (All pts) (Survivors) (Survivors) Median with 95% CI for change in LVESVI from baseline to 1 yr Z=1.33, p=0.18 (All pts)

Recurrent MR at 1 year

LVESVI with Recurrent MR p < 0.001

Primary end point LVESVI (ml/m2)MR ≥2+ (%) RIME Trial CABG67.4 (-6%)50 CABG + MV repair56.2 (-28%)4 P-value0.002<0.001 CTSN Mod MR Trial CABG46.1 (-17%)30 CABG + MV repair49.6 (-16%)11 P-valueNS<0.001 CTSN Severe MR Trial CABG + MV repair (overall)54.6 (-11%)33 CABG + MV repair (recurrent MR)64.1 (+5%)100 CABG + MV repair (no recurrent MR)47.3 (-22%)0 CABG + MV replacement60.7 (-10%)2 Comparison with other randomised controlled trials

Mortality 30 Day Mortality: 1.6% (repair) vs. 4.0% (replacement), p = Month Mortality: 14.2% (repair) vs. 17.6% (replacement), p =0.47

MACCE at 12 Months

Serious Adverse Events P=NS

Quality of Life at 1 year Δ=16.6% Δ=18.4%Δ=46.9% Δ=19.6%

NYHA Classification & Death

Restrictive mitral valve annuloplasty versus mitral valve replacement for functional ischemic mitral regurgitation: Am exercise echocardiographic study. Fino et al. J Thorac Cardiovasc Surg 2014;148: Physio-17% 28 Physio-51% 30 Physio-29% 32 Physio-3% 27 CE-23% 29 CE-26% 31 CE-3% 27 SJ-8% 29 SJ-26% 25 SJ-3% 27 Carbomedics-8% 29 Carbomedics-3% MV Repair-35 MVR - 35

Restrictive mitral valve annuloplasty versus mitral valve replacement for functional ischemic mitral regurgitation: Am exercise echocardiographic study. Fino et al. J Thorac Cardiovasc Surg 2014;148:447-53

Determinants of long term functional capacity in patients undergoing mitral valve annuloplasty or mitral valve replacement for ischemic mitral regurgitation. Fino et al. AHA Nov 2014

10 Variable Model of MR Recurrence and/or Death Age BMI Gender Race EROA Basal Aneurysm NYHA History of CABG History of PCI History of Ventricular Arrhythmia

ROC Curve: 10 Variable model of Recurrence/Death

Basal Aneurysm

Preoperative 3D Valve AnalysisPredicts Recurrent IMR after Mitral Annuloplasty—Gorman lab 50 pts with Severe IMR undergoing MV repair with small annuloplasty ring comparing recurrence of mod to severe MR to those without recurrence

Conclusions -2D echocardiographic studies identified different predictors of IMR recurrence, but results are inconsistent and generally inadequate to predict IMR recurrence -3D echocardiography combined with valve modeling is predictive of recurrent IMR -Preoperative regional leaflet tethering of P3 is a strong independent predictor of IMR recurrence after undersized ring annuloplasty -In patients with IMR and a preoperative P3 tethering angle ≥29.9° chordal- sparing mitral valve replacement rather than mitral valve repair should be strongly considered

Repair vs Replacement for Severe Ischemic MR Does it result in improved survival? – Early/late?--NO Does it result in decreased complications? – NO (at one year) Does it result in more LV reverse remodeling? – NO (at one year) Does it result in improved freedom from hospitalizations or symptoms of heart failure? – NO (at one year) Is Replacement a more reliable operation for longterm freedom from recurrent MR? -YES (longterm benefits will be seen because of absence of MR ?) -Can we predict recurrence? -Predictive models of recurrence of IMR are being developed to allow for customization of repair vs replacement for individual pt with severe IMR

Conclusions Recurrent MR at least to a moderate degree occurs early (6mo) and is a common event at 2 years after MV repair with an undersized annuloplasty ring— clinical impact yet unkown? MVR provides a more durable correction of severe IMR with no differences seen in reversal of LV remodeling or clinical outcomes – MR recurrence may have an important effect on long-term outcomes MVR with complete chordal sparing is a safe and acceptable option in pts with severe IMR-supported by LEVEL of EVIDENCE “A”

So What Do I Do? I continue to repair about 70% of IMR with small complete annuloplasy ring while replacing about 30% – Degree of tethering; age of pt; need for anticoagulation; – Await 2 and 5 year data on effect of recurrent moderate MR on clinical outcome 2 year follow-up to be presented AHA Nov 2015